HighGravityDataUnitedHealth Group — Apr 21, 2026 release
Fiscal 2026 first-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000731766-26-000121
Showing in the filing
Adjusted diluted earnings per share
“> $18.25”
Period
FY2026
Measure
Company-defined measure
Source
Guidance table
All guidance in this release · 12
Earnings outlook for FY2026
“Greater Than $17.35 Per Share”
Adjusted earnings outlook for FY2026
“Greater Than $18.25 Per Share”
Alegeus Technologies acquisition earnings im… for FY2026
“earnings neutral to 2026”
Share repurchase for Q2 FY2026
“at least $2 billion”
Long-term debt-to-capital ratio target for the long term
“approximately 40.0%”
Timing to reach long-term debt-to-capital ra… for the long term
“expects to reach that level in the back half of 2026”
Stock repurchase for Q2 FY2026
“at least $2.0 billion”
Projected 2026 expected reduction of loss co… for FY2026
“$402 million”
Net earnings attributable to UnitedHealth Gr… for FY2026
“> $15,800”
Adjusted net earnings attributable to United… for FY2026
“> $16,610”
Diluted earnings per share for FY2026
“> $17.35”
Adjusted diluted earnings per share for FY2026
“> $18.25”
Exhibit 99.1 · the passage around this item
… earlier in the release
0.22 — ~(0.20) Tax effect of adjustments per share ......................................................................................................................................... (0.09) (0.11) ~(0.30) Adjusted diluted earnings per share ................................................................................................................................. $7.23 $7.20 > $18.25 End Notes (1) Net portfolio divestitures and South American impacts for the three months ended March 31, 2026 includes net gains on dispositions and businesses held for sale and $72 million of incremental losses related to South American businesses held for sale. For the three months ended March 31, 2025, net gains on dispositions and South American impacts were not significant. (2) Restructuring and other for the three months ended March 31, 2026 includes net valuation gains on equity securities. For the three months ended March 31, 2025 net valuation gains were not significant. Page 16 of 16
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.